NHSN Reporting: Adverse Drug Events - Glycemic Control
0.1.0 - CI Build

NHSN Reporting: Adverse Drug Events - Glycemic Control, published by HL7 International - Public Health Work Group. This is not an authorized publication; it is the continuous build for version 0.1.0). This version is based on the current content of https://github.com/HL7/fhir-nhsn-ade-ig/ and changes regularly. See the Directory of published versions

## Home Page

### Overview

Adverse drug events (ADEs) are among the most common causes of iatrogenic harm in U.S. hospitals. An effort to establish an EHR- and vendor-neutral standard for submitting ADE data to NHSN is being sought to improve patient safety and facilitate quality improvement effort. This promising initiative enables EHRs of acute care facilities to serve as source systems for reporting ADE data to the National Healthcare Safety Network (NHSN) via industry electronic messages. This initiative leverages NHSN’s longstanding experience working closely with the Health Level Seven (HL7) standards development organization and HL7 consultants in developing and maintaining electronic healthcare-associated and antibiotic use and resistance reporting implementation guidance for EHRs and infection surveillance system vendors in the acute care arena. That experience, and the working relationships developed over a 10-year partnership, are an important foundation for a collaborative effort in which NHSN, HL7, HL7 consultants, and EHR vendors join forces to advance the field of electronic ADE reporting. These long-standing linkages links between public health and vendors can be leveraged in ways that yield benefits for surveillance and prevention that are tightly coupled to business models and growth.

#### Hypoglycemia

The first module, Hypoglycemia, as part of the NHSN Medication Safety Component, enables hospitals to track and benchmark inpatient medication-related hypoglycemia (low blood sugar). Inpatient hypoglycemia can be severe and life-threatening and is associated with longer hospital stays and increased medical costs. Severe hypoglycemia (<40 mg/dL) occurs in 2%-5% of hospitalized patients with diabetes mellitus (DM). Medication-related hypoglycemic events are common causes of adverse drug events (ADEs) occurring in inpatient settings, with rates of severe hypoglycemia varying across hospitals, suggesting opportunities for improvement in the quality of care. Measurement of medication-related hypoglycemia in a meaningful and standardized way may improve glycemic management. The NHSN ADE – Hypoglycemia Module provides a mechanism for facilities to report and analyze medication-related hypoglycemia as part of patient safety and glycemic management quality improvement efforts.

The hypoglycemia module is based on quality reporting metrics previously- or currently-endorsed by the National Quality Forum (NQF): NQF #2363 Glycemic Control - Hypoglycemia and NQF #3503 Hospital Harm – Severe Hypoglycemia. The metrics reported in this module would be primarily based on linked eMAR (antidiabetic medication administration) and laboratory (blood glucose) data.

#### Hyperglycemia

This work is now being extended to include the hyperglycemia (high blood sugar) model. Similar to inpatient hypoglycemia, hyperglycemia in hospitalized patients is associated with excess morbidity, mortality, and medical costs. Patients with diabetes comprise 30% to 40% of U.S. hosptial admissions and 70% to 80% of critical care stays. In patients with and without diabetes, appropriate management of hyperglycemia in hospital settings has been associated with improved clinical outcomes, reduced hospital-related morbidity and mortality, and lower costs. The incorporation of hyperglycemia surveillance is important for ensuring a comprehensive and balanced glycemic management quality improvement effort for hospitals. The NHSN ADE – Glycemic Control Module would provide a mechanism for facilities to report and analyze both inpatient hypoglycemia and hyperglycemia as part of patient safety and glycemic management quality improvement efforts.

The hyperglycemia module is based on quality reporting metrics currently-endorsed by the National Quality Forum (NQF): NQF #3533e Hospital Harm – Severe Hyperglycemia. The metrics reported in this module are intended to be based on linked diabetes diagnosis, eMAR (antidiabetic medication administration) and laboratory (blood glucose) data.

### Authors

Name | Email/URL
--- | ---
HL7 International - Public Health | http://www.hl7.org/Special/committees/pher